Patents by Inventor Andrew Vaillant

Andrew Vaillant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230056788
    Abstract: The present disclosure relates to methods for the inhibition of proteins involved in the assembly and or secretion of HBV SVP by inhibiting the activity of casein kinase 1 isoform delta, DNAJB12, and/or microtubule-actin crosslinking factor 1.
    Type: Application
    Filed: February 18, 2021
    Publication date: February 23, 2023
    Inventors: Andrew VAILLANT, Richard BOULON, Matthieu BLANCHET, Patrick LABONTE
  • Patent number: 9616083
    Abstract: It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate complexes.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: April 11, 2017
    Assignee: REPLICOR INC
    Inventors: Michel Bazinet, Andrew Vaillant
  • Patent number: 9603865
    Abstract: It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus/hepatitis delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: March 28, 2017
    Assignee: REPLICOR INC.
    Inventor: Andrew Vaillant
  • Patent number: 9533003
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: January 3, 2017
    Assignee: REPLICOR INC.
    Inventors: Michel Bazinet, Andrew Vaillant
  • Patent number: 9492506
    Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 15, 2016
    Assignee: REPLICOR INC.
    Inventors: Michel Bazinet, Andrew Vaillant
  • Publication number: 20160263143
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Application
    Filed: September 15, 2015
    Publication date: September 15, 2016
    Inventors: Michel Bazinet, Andrew Vaillant
  • Patent number: 9284556
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: March 15, 2016
    Inventors: Michel Bazinet, Andrew Vaillant
  • Publication number: 20160008393
    Abstract: It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus/hepatits delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.
    Type: Application
    Filed: July 8, 2015
    Publication date: January 14, 2016
    Inventor: Andrew VAILLANT
  • Patent number: 9200283
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: December 1, 2015
    Inventors: Michel Bazinet, Andrew Vaillant
  • Patent number: 9133458
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 15, 2015
    Assignee: REPLICOR INC.
    Inventors: Michel Bazinet, Andrew Vaillant
  • Publication number: 20140369963
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Application
    Filed: August 1, 2014
    Publication date: December 18, 2014
    Inventors: Michel Bazinet, Andrew Vaillant
  • Publication number: 20140369962
    Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Application
    Filed: August 1, 2014
    Publication date: December 18, 2014
    Inventors: Michel Bazinet, Andrew Vaillant
  • Patent number: 8716259
    Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: May 6, 2014
    Assignee: Replicor Inc.
    Inventors: Andrew Vaillant, Michel Bazinet
  • Publication number: 20140065102
    Abstract: It is disclosed a method for the treatment of HBV infection or HBV/HDV co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
    Type: Application
    Filed: May 17, 2013
    Publication date: March 6, 2014
    Inventors: Michel BAZINET, Andrew VAILLANT
  • Publication number: 20130310445
    Abstract: It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate complexes.
    Type: Application
    Filed: May 17, 2013
    Publication date: November 21, 2013
    Inventors: Michel BAZINET, Andrew VAILLANT
  • Publication number: 20130309201
    Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.
    Type: Application
    Filed: May 17, 2013
    Publication date: November 21, 2013
    Inventors: Michel BAZINET, Andrew VAILLANT
  • Patent number: 8513211
    Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: August 20, 2013
    Assignee: Replicor Inc.
    Inventors: Andrew Vaillant, Michel Bazinet
  • Publication number: 20120184601
    Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.
    Type: Application
    Filed: July 14, 2011
    Publication date: July 19, 2012
    Inventors: Andrew VAILLANT, Joan-Marc Juteau
  • Publication number: 20120046348
    Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.
    Type: Application
    Filed: August 18, 2011
    Publication date: February 23, 2012
    Applicant: REPLICOR INC.
    Inventors: Andrew Vaillant, Michel Bazinet
  • Patent number: 8067385
    Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: November 29, 2011
    Assignee: Replicor, Inc.
    Inventors: Andrew Vaillant, Jean-Marc Juteau